1. Neuronal Signaling Protein Tyrosine Kinase/RTK Apoptosis
  2. Trk Receptor Apoptosis
  3. Larotrectinib

Larotrectinib  (Synonyms: LOXO-101; ARRY-470)

目录号: HY-12866 纯度: 99.95%
Data Sheet SDS COA 产品使用指南

Larotrectinib (LOXO-101) 是一种 ATP 竞争性的、口服选择性抑制剂,对原肌凝蛋白相关激酶 (TRK) 家族受体的三个亚型 (TRKA,B 和C) 具有纳摩尔级别的 50% 抑制浓度。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Larotrectinib Chemical Structure

Larotrectinib Chemical Structure

CAS No. : 1223403-58-4

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥880
In-stock
1 mg ¥363
In-stock
5 mg ¥800
In-stock
10 mg ¥980
In-stock
50 mg ¥2600
In-stock
100 mg ¥3880
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Larotrectinib:

查看 Trk Receptor 亚型特异性产品:

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

IC50 & Target[1][2]

TrkA

 

TrkB

 

TrkC

 

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 10 μM
Compound: 1
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 35007864]
BaF3 GI50
> 10 μM
Compound: 1; LOXO-101
Antiproliferative activity in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
Antiproliferative activity in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
[PMID: 32949955]
BaF3 IC50
> 10 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
> 1000 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G623R mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G623R mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
> 3 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells habouring TRKA G595R mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against mouse BaF3 cells habouring TRKA G595R mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 35007864]
BaF3 IC50
0.007 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC assessed as cell growth inhibition incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC assessed as cell growth inhibition incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
0.009 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA assessed as cell growth inhibition incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA assessed as cell growth inhibition incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
0.013 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK3 (unknown origin) assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK3 (unknown origin) assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
0.016 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type CD74-NTRK1 (unknown origin) assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type CD74-NTRK1 (unknown origin) assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
0.04 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK2 (unknown origin) assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK2 (unknown origin) assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
0.054 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK3 (unknown origin) harbouring G696A mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK3 (unknown origin) harbouring G696A mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
0.11 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G667C mutant assessed as cell growth inhibition incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G667C mutant assessed as cell growth inhibition incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
0.184 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type CD74-NTRK1 (unknown origin) harbouring G667C mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type CD74-NTRK1 (unknown origin) harbouring G667C mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
0.539 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type CD74-NTRK1 (unknown origin) harbouring G595R mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type CD74-NTRK1 (unknown origin) harbouring G595R mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
1 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing CD74 fused TrkA assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing CD74 fused TrkA assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
1.201 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK3 (unknown origin) harbouring G623R mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK3 (unknown origin) harbouring G623R mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
1.55 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G595R mutant assessed as cell growth inhibition incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G595R mutant assessed as cell growth inhibition incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
10.1 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G667A mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G667A mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
11 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkA assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkA assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
1256 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA G667C mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA G667C mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
14.8 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G696A mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G696A mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
1487 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkC G623R assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkC G623R assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
173 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC V573M mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC V573M mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
18.4 nM
Compound: LOX0-101
Antiproliferative activity against mouse BaF3-LMNA-NTRK1 cells assessed as cell viability measured after 72 hrs
Antiproliferative activity against mouse BaF3-LMNA-NTRK1 cells assessed as cell viability measured after 72 hrs
[PMID: 33069129]
BaF3 IC50
2.24 μM
Compound: 1
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK2 (unknown origin) harbouring G639R mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
Antiproliferative activity against mouse BaF3 cells transfected with wild type ETV6-NTRK2 (unknown origin) harbouring G639R mutation assessed as cell viability measured after 72 hrs by Micro plate reader method
[PMID: 32702585]
BaF3 IC50
2504.7 nM
Compound: LOX0-101
Antiproliferative activity against mouse BaF3-LMNA-NTRK1-G595 mutant cells assessed as cell viability measured after 72 hrs
Antiproliferative activity against mouse BaF3-LMNA-NTRK1-G595 mutant cells assessed as cell viability measured after 72 hrs
[PMID: 33069129]
BaF3 IC50
321 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA G667S mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA G667S mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
332 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G696C mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G696C mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
3570 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
38.2 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G667S mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing CD74 fused TRKA G667S mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
4060 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA G595R mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA G595R mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
46 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G696S mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G696S mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
BaF3 IC50
547 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA F589L mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing LMNA fused TrkA F589L mutant assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
586 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkC G696C assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkC G696C assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
59 nM
Compound: Larotrectinib
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkC assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing TEL fused TrkC assessed as inhibition of cell growth incubated for 3 days by CCK-8 assay
[PMID: 35080890]
BaF3 IC50
96 nM
Compound: 1
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G623E mutant incubated for 3 days by CCK8 assay
Antiproliferative activity against mouse BaF3 cells expressing ETV6 fused TRKC G623E mutant incubated for 3 days by CCK8 assay
[PMID: 35426680]
KM12 IC50
0.005 μM
Compound: 1
Antiproliferative activity against human KM12 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human KM12 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 35007864]
KM12 IC50
0.012 μM
Compound: 1; LOXO-101
Antiproliferative activity against human KM12 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human KM12 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
[PMID: 36760745]
MCF7 IC50
> 10 μM
Compound: 1
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 35007864]
MCF7 IC50
> 40 μM
Compound: 1; LOXO-101
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
[PMID: 36760745]
体外研究
(In Vitro)

Larotrectinib (LOXO-101) 是原肌球蛋白相关激酶 (TRK) 受体激酶家族 (TRKA、B 和 C) 的 ATP 竞争性口服抑制剂,对所有三种亚型具有低纳摩尔半抑制浓度,以及相对于其他激酶的选择性大于 1,000 倍[1][2]。用 Larotrectinib (LOXO-101) 处理后的增殖测量表明,所有三种细胞系的细胞增殖都受到剂量依赖性抑制。对 CUTO-3.29 的 IC50 小于 100 nM,KM12 和 MO-91 的 IC50 小于 10 nM,这与该药物对 TRK 激酶家族的已知效力一致[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在大鼠和猴子研究中,Larotrectinib (LOXO-101) 表现出 33-100% 的口服生物利用度和 60-65% 的血浆蛋白结合率。它具有低脑渗透性,并且在 28 天 (d) GLP 毒理学研究中具有良好的耐受性。单剂量 (30 mg/kg) Larotrectinib (LOXO-101) 可降低肿瘤中 TRKA 的酪氨酸磷酸化和下游信号转导 (pERK) >80%[1]。注射 KM12 细胞的无胸腺裸鼠每天口服 Larotrectinib (LOXO-101),持续 2 周。观察到剂量依赖性肿瘤抑制,证明了这种选择性化合物在体内抑制肿瘤生长的能力[4]。与媒介物处理的小鼠相比,Larotrectinib (LOXO-101) (200 mg/kg/天,口服给药,持续六周) 可将骨髓和脾脏中的白血病浸润减少到检测不到的水平。根据 Xenogen 成像的测定,接受 Larotrectinib (LOXO-101) 处理的小鼠在停止处理 4 周后仍然存活并且没有白血病[5]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT04142437Bayer
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
April 3, 2020
NCT05192642Bayer
Solid Tumors Harboring NTRK Fusion
December 3, 2021
NCT05236257Bayer
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion|Infantile Fibrosarcoma
March 10, 2022
分子量

428.44

Formula

C21H22F2N6O2

CAS 号
性状

固体

颜色

White to yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性数据
细胞实验: 

DMSO 中的溶解度 : ≥ 4.6 mg/mL (10.74 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3340 mL 11.6702 mL 23.3405 mL
5 mM 0.4668 mL 2.3340 mL 4.6681 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.84 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.84 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

扫码获得
动物溶解方案

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO PEG300/PEG400Tween 80,均可在 MCE 网站选购。
纯度 & 产品资料

纯度: 99.95%

参考文献
Animal Administration
[4]

Mice[4]
Athymic nude mice are used throughout the study. 5×105 KM12 cells are injected subcutaneously into the dorsal flank area of the mice. Tumor volume is monitored by direct measurement with calipers and calculated by the formula: length × (width2)/2. Following the establishment of tumor and when the tumor size is between 150-200 mm2, mice are randomly selected to receive diluent, 60 mg/kg/dose or 200 mg/kg/dose of Larotrectinib (LOXO-101). Larotrectinib (LOXO-101) is administered by oral gavage once daily for 14 days. After the last dose, tissue and blood are collected at 3, 6 and 24 hours post-treatment[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3340 mL 11.6702 mL 23.3405 mL 58.3512 mL
5 mM 0.4668 mL 2.3340 mL 4.6681 mL 11.6702 mL
10 mM 0.2334 mL 1.1670 mL 2.3340 mL 5.8351 mL

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Larotrectinib
目录号:
HY-12866
需求量:
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》